企業プロフィール
Fortress Biotech 株価・ニュース・カタリスト
- ティッカー:
- FBIO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
2.77 USD (-2.81%)
終値
最終更新: 2026年8月20日
88M USD
時価総額
株価変動の要因
As of Aug 20, 2026, FBIO closed down 2.81% at $2.77. No new same-company headline was identified in the current news window.
企業概要
Multi-Asset Biopharmaceutical Holding Company
Fortress Biotech creates value by acquiring, forming, and advancing biopharmaceutical businesses and assets. Its portfolio includes commercial prescription products, development-stage programs, controlled subsidiaries, and minority investments across oncology, dermatology, and rare diseases.
Decentralized Company-Building Model
Fortress frequently places individual assets within focused subsidiaries that can raise capital, form partnerships, or pursue strategic transactions independently. The parent company retains value through equity ownership, royalties, milestones, and other contractual economics.
Rare Disease and Commercial Assets
Subsidiary Cyprium obtained FDA approval for ZYCUBO in Menkes disease and monetized the associated Rare Pediatric Disease Priority Review Voucher. Following Sun Pharma’s acquisition of Checkpoint, Fortress retains long-term royalty exposure to UNLOXCYT.
Multiple Monetization Pathways
Fortress can realize value through commercial product revenue, subsidiary transactions, priority review vouchers, royalties, milestone payments, and retained equity interests. This structure means portfolio value may be created through regulatory success or strategic transactions at individual subsidiaries.
Partnership-Sourced Pipeline
Fortress sources programs through collaborations with organizations including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber, and Sentynl. Avenue’s acquisition of ATX-04 from Duke University adds a clinically validated program in Pompe disease.
今後のカタリスト
- Triplex clinical data in patients co-infected with HIV and cytomegalovirus by the end of 2026.
- Initiation of the MB-109 study in recurrent glioblastoma and high-grade astrocytoma in the fourth quarter of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。